Novartis' Cosentyx to Achieve Blockbuster Sales

Novartis' Cosentyx to Achieve Blockbuster Sales

The FDA's recent approval of Novartis' Cosentyx for the treatment of adults with active ankylosing spondylitis (AS) and psoriatic arthritis (PsA), will propel the drug to blockbuster status, as it now has three approved indications in the US and Europe

(Visited 3 times, 1 visits today)
5
Like
Save

Comments

Comments are disabled for this post.